Table 1.
COVID-19 vaccines and their excipients analyzed by the lymphocyte transformation test (LTT).
| Vaccine | ChAdOx1 (Vaxzevria) |
BNT162b2 (Comirnaty) |
NVX-CoV2373 (Nuvaxovid) |
|---|---|---|---|
| Type of vaccine | Adenovirus | mRNA | Recombinant protein |
| Manufacturer | Astra Zeneca | Pfizer | Novavax |
| Dosage level | 0.5 ml − 5 × 1010 viral particles per dose | 0.3 ml (30 µg/Dose) | 0.5 ml (5 µgspike protein + MatrixM adjuvant) |
| Excipients tested | Polysorbate-80 | 2[(polyethyleneglycol)-2000]-N,N-ditetradecylacetamide (PEG 2050) |
Polysorbate-80 |
| Vaccinetest dilutions (LTT) | 1:200 1:400 1:800 1:1600 1:3200 1:6400 |
1:200 1:400 1:800 1:1600 1:3200 1:6400 |
1:200 1:400 1:800 1:1600 1:3200 1:6400 |
| Excipient dilutions tested | Polysorbate-80 (Sigma) 0.2% 0.1% 0.05% 0.025% 0.125% 0.00625% |
PEG 2050 (Sigma) 0.5% 0.25% 0.125% 0.0625% 0.0312% 0.0156% |
N/A |